D
uring normal mitochondrial function, a small percentage of electrons from the electron transport chain reduce oxygen to form superoxide (O 2 . ). In several common conditions, such as atherosclerosis, 1,2 ischemia/reperfusion injury and aging, [3] [4] [5] [6] [7] the mitochondria become dysfunctional and this leak of electrons is increased. 1 The mitochondria contain a unique form of superoxide dismutase (SOD), the manganesecontaining mitochondrial SOD (SOD2), which is critical in protecting against excessive production of O 2 . . Mice lacking this enzyme die of a cardiomyopathy within 10 days of birth and mice lacking one allele of SOD2 (SOD2 ϩ/Ϫ mice) develop hypertension with aging and in response to a high salt diet. 8 The development of hypertension in SOD2 ϩ/Ϫ mice is in keeping with a role of reactive oxygen species (ROS) in the pathogenesis of this and many other vascular diseases. 9 Hypertension has been associated with increased ROS production in the vasculature, the kidney and in portions of the central nervous system that control blood pressure. The hormone angiotensin II (Ang II), commonly implicated in hypertension, increases ROS production in the sites. Moreover, ROS overproduction leads to decreased bioavailability of NO, impairs endothelium-dependent vasodilatation, and promotes vasoconstriction. These alterations occur early in the development of vascular disease. 10 There is substantial interest in the enzymatic source of ROS in hypertension. Ang II stimulates the NADPH oxidase in many mammalian cells via pathways involving protein kinase C and the tyrosine kinase c-Src. 11 Ang II also activates the NADPH oxidase in vivo and mice lacking components of this enzyme are resistant to both Ang II and salt-dependent hypertension. Specific inhibitors of the NADPH oxidase have antihypertensive effects. 12, 13 Another potential source of ROS in hypertension is the mitochondria. We have previously found that Ang II increases production of mitochondrial ROS, decreases mitochondrial membrane potential, and reduces the respiratory control ratio. 14 These deleterious effects of Ang II on mitochondrial function were associated with increased cellular O 2 . production and decreased endothelial NO bioavailability. These studies further indicated that Ang II activation of the NADPH oxidase led to oxidant disruption of mitochondrial function, supporting an important interplay between these 2 sources of ROS, 14 and suggest that mitochondria-derived ROS could contribute to endothelial dysfunction and hypertension. In keeping with this concept, Widder et al recently showed that mice transgenic for the mitochondrial antioxidant enzyme thioredoxin 2, are resistant to Ang II-induced hypertension and endothelial dysfunction. 15 Taken together, these studies suggest that mitochondrial-produced ROS could play an important role in hypertension.
We therefore performed the present study to test the hypothesis that mitochondrial-targeted antioxidant therapy would be effective in both preventing and treating hypertension. To gain further insight into the role of mitochondrial O 2 . in endothelial dysfunction and hypertension, we examined the effects of depleting or overexpressing mitochondrial superoxide dismutase (SOD2) in cultured endothelial cells and transgenic mice with Ang II-induced hypertension. Our data strongly indicate that mitochondrial O 2 . is an important, previously largely ignored, therapeutic target to treat endothelial dysfunction and high blood pressure.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Reagents
MitoTEMPO, mitoTEMPO-H, 1-hydroxy-3-carboxy-pyrrolidine (CPH), and nitroxide 3-carboxy-proxyl (CP) were purchased from Alexis Corporation (San Diego, Calif). Xanthine oxidase was purchased from Roche Molecular Biochemicals (Indianapolis, Ind). All other reagents were obtained from Sigma (St Louis, Mo).
Cell Culture
Bovine aortic endothelial cells (BAECs) (passage 4 to 8) were cultured on 100-mm plates in media 199 containing 10% FCS supplemented with 2 mmol/L L-glutamine and 1% vitamins. Confluent cells were used for the experiments. 16 Human aortic endothelial cells (HAECs) purchased from Lonza (Chicago, Ill) and cultured in EGM-2 medium supplemented with 2% FBS but without antibiotics. On the day before the study, the FBS concentration was reduced to 1%. In preliminary experiments, we examined the effect of varying doses of Ang II on cellular O 2 . production. We found that 4 hours of Ang II increased cellular O 2 . in a dose-dependent manner with maximum stimulation at 200 nmol/L (Online Figure I ). This concentration was therefore used in the remainder of the experiments. It should be noted that because degradation in culture, the steady-state concentration of Ang II is substantially lower than that initially added. 17 
Mitochondrial Isolation and Study
Mitochondria were isolated as previously described. 18 Complex I-dependent (glutamate plus malate as substrate) or complex II-dependent (succinate as the substrate) mitochondrial respiration was studied using intact mitochondria 14 
Measurement of Cellular O 2 . , NADPH Oxidase
Activity, and NO Levels Superoxide was measured using dihydroethidium (DHE) and an high-performance liquid chromatography (HPLC)-based assay with minor modification as described previously. 21 NADPH oxidase activity was measured in membrane preparations prepared as described previously using electron spin resonance (ESR) and the spin probe CPH, 22 and was quantified as NADPH dependent O 2 . production. NO levels in endothelial cells and vessels were quantified by ESR and colloid Fe(DETC) 2 as described previously. 23 
Modulation of SOD2 Expression
To manipulate mitochondrial O 2 . , we inhibited the expression of mitochondrial SOD2 using small interfering (si)RNA from Qiagen or overexpressed SOD2 using transfection-ready expression plasmid for human SOD2 (Addgene Inc). As a control we used nonsilencing siRNA (Qiagen AllStars negative control) and a green fluorescent protein (GFP) empty plasmid (Lonza). The plasmids were grown in bacteria using standard techniques and purified with a kit (Sigma).
Animal Experiments
Hypertension was induced by Ang II (490 ng/kg per minute) as described previously 24 
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cle as described in the figure legends. In other animals, mitoTEMPO treatment was started seven days after saline or Ang II minipump placement. Blood pressure was monitored using either the tail cuff method or telemetry as previously described. 25, 26 Following 14 days of Ang II infusion, the animals were euthanized by CO 2 inhalation and aortas were extracted for the analysis of NO and O 2 . production, and endothelial functions. DOCA salt-induced hypertension was induced as described previously 27 using C57Bl/6 mice. Ten days after surgery, the mice were implanted with osmotic pumps containing saline or mitoTEMPO (0.7 mg/kg per day). Seventeen days after surgery, the animals were euthanized by CO 2 inhalation and segments of mouse aorta were used for analysis of vascular NO and O 2 .
production. Endothelium-dependent vasodilatation was analyzed in isolated 3-mm aortic segments in organ chambers as we have previously described. 26 
Statistics
Experiments were analyzed using the Student-Neuman-Keuls post hoc test and ANOVA. P levels of Ͻ0.05 were considered significant.
Results

Mitochondrial Accumulation of mitoTEMPO
It has been previously suggested that conjugation to a lipophilic triphenylphosphonium cation allows targeting of an antioxidant to the mitochondria and can prevent mitochondrial oxidative damage and mitochondrial dysfunction. 28 , 29 We have developed a new mitochondria-targeted superoxide dismutase mimetic mitoTEMPO ( Figure 1A ).
To confirm mitochondrial accumulation of mitoTEMPO we used ESR to examine the relative intensities of the nitroxide signal in the cell media, mitochondria and cytoplasm following one hour incubation with mitoTEMPO. As evidenced in Figure 1A , the mitoTEMPO accumulation in the cytoplasm fraction was 3-fold greater than that present in the extracellular media, whereas analysis of the mitochondria revealed substantial accumulation of mito-TEMPO up to 15 mol/L.
Scavenging of O 2 . by MitoTEMPO
In additional experiments, we examined the capacity of mitoTEMPO or its reduced form, mitoTEMPO-H, to scavenge O 2 . . We used the spin trap EMPO and generated O 2 . using xanthine and xanthine oxidase. As evident in Figure 1B , exposure of EMPO to xanthine/xanthine oxidase produced an ESR spectrum typical of the EMPO-OOH radical adduct. Addition of either mitoTEMPO or mitoTEMPO-H inhibited formation of EMPO-OOH radical adduct in dose dependent manner ( Figure 1B and 1C) . Control experiments showed that neither mitoTEMPO nor mitoTEMPO-H had a direct effect on xanthine oxidase activity (Online Figure II) . The estimated IC 50 's for Figure 1A and demonstrate specificity of this agent for mitochondrial protection against O 2 . .
Effect of MitoTEMPO on Production of Mitochondrial ROS and Respiration
We previously reported that Ang II increases mitochondrial ROS production and impairs mitochondrial respiration in endothelial cells. 14 We therefore sought to determine whether mitoTEMPO would ameliorate these effects. fluorescence colocalized with the mitochondria as detected using the probe mitoTracker (Figure 2A To perform these studies, we stimulated BAECs with Ang II (200 nmol/L for 4 hours) and then exposed the cells to mitoTEMPO (25 nmol/L) for 15 minutes. Membrane fractions were then produced by centrifugation and NADPH oxidase activity measured using ESR. It was found that Ang II significantly increased nonmitochondrial NADPH oxidase activity ( Figure 2B ). Treatment of cells with mitoTEMPO completely blocked the increase in NADPH oxidase activity caused by Ang II but did not affect basal NADPH oxidase activity in unstimulated cells ( Figure 2B ). Importantly, supplementation with a mitochondria impermeable SOD-mimetic CP did not affect NADPH oxidase activity. Direct addition of mitoTEMPO (0.5 mol/L) to membrane fractions did not affect NADPH oxidase activity (Online Figure V) .
This decrease of NADPH oxidase activity in mito-TEMPO treated cells was accompanied by reduced production of cellular O 2 . measured in intact cells using dihydroethidium and HPLC ( Figure 2C ) and an increase in endothelial NO production as detected by ESR and the spin trap Fe[DETC] 2 ( Figure 2D ). Treatment of Ang II-stimulated cells with the mitochondria impermeable analog 3-carboxyproxyl 29 had no effect on these parameters (Figure 2C and 2D 
SOD2 Modulates Ang II-Stimulated Cellular O 2 . and NADPH Oxidase Activity
It is conceivable that the effects of mitoTEMPO are not mediated by O 2 . scavenging but are attributable to nonspecific effects. We therefore performed additional experiments to manipulate the levels of mitochondrial superoxide dismutase (SOD2) and measured NADPH oxidase activity and cellular O 2 . production. Transfection of HAECs with an SOD2 plasmid increased mitochondrial SOD2 activity by 2.4-fold, whereas cytoplasmic SOD1 activity was not changed (Table 1) . Depletion of SOD2 with siRNA decreased SOD2 activity by 2.7-fold (Table 1 ). In cells transfected with a GFP control plasmid, Ang II stimulation doubled NADPH oxidase activity. In contrast, Ang II had no effect on NADPH oxidase activity in HAECs transfected with the SOD2 plasmid ( Figure 3A) . Interestingly, depletion of SOD2 using siRNA transfection increased NADPH oxidase activity in unstimulated cells compared to cells transfected with nonsilencing control RNA. Furthermore, Ang II stimulation of SOD2 depleted cells resulted in higher activity of NADPH oxidase compared to cell treated with either nonsilencing RNA or a control GFP plasmid ( Figure 3A) . Analysis of intact cells showed that Ang II increased the O 2 . to a similar extent in nontransfected cells or cells treated with a GFP control plasmid ( Figure 3B ). SOD2 overexpression completely prevented Ang II-stimulated O 2 . production while not affecting O 2 . production in unstimulated cells. In keeping with its effect on NADPH oxidase activity, SOD2 depletion enhanced both basal and Ang II-stimulated O 2 . in intact cells ( Figure 3B ). These data confirmed that modulation of mitochondrial O 2 . by mitoTEMPO or changing SOD2 levels affects production of cellular O 2 . by NADPH oxidase.
Fluorescent microscopy with MitoSOX showed that SOD2 depletion increased both basal and Ang II -stimulated mitochondrial superoxide production, and that this could be inhibited by mitoTEMPO (Online Figure VI) . It is important to note that mitoTEMPO treatment inhibited cellular O 2 . and mimicked SOD2 overexpression ( Figure 3B ) in SOD2 depleted cells, further validating mitoTEMPO as an SOD2 mimetic.
Antihypertensive Effect of MitoTEMPO
Increased vascular O 2 . production has been implicated in the pathogenesis of endothelial dysfunction and hypertension. 9, 34 Because mitoTEMPO diminished mitochondrial ROS, inhibited Ang II-stimulated endothelial O 2 . and prevented inactivation of NO caused by Ang II in cultured endothelial cells (Figures 2 and 3) , we hypothesized that it could improve endothelial function and decrease hypertension in vivo. Coinfusion of mitoTEMPO ( Figure 4A ) significantly attenuated the Ang II-induced hypertension in a dose-dependent manner (50, 150 and 500 g/kg per day), while not affecting blood pressure in normal mice. Telemetric measurements of blood pressure confirmed that coinfusion of mitoTEMPO (150 g/kg per day) with Ang II markedly attenuated hypertension ( Figure 4B ). In addition, mitoTEMPO inhibited the increase in vascular O 2 .
( Figure 4C ) and prevented the decrease of vascular NO ( Figure 4D ) caused by Ang II infusion. Importantly, infusion of the same dose of the nontargeted SOD mimetic TEMPOL (286 nmol/kg per day) did not affect Ang II-induced hypertension ( Figure 4A ). These data demonstrate that the mitochondrial-targeted SOD2 mimetic mitoTEMPO attenuates Ang II-induced hypertension at an extremely low dose. The above studies showing that mitoTEMPO can prevent hypertension do not provide insight into whether it could lower blood pressure after hypertension is established. We therefore performed additional studies in which mitoTEMPO was administered after the onset of Ang II-induced hypertension. Following seven days of Ang II infusion (0.7 mg/kg per day) systolic blood pressure reached 160 mm Hg ( Figure 5A ). The subsequent addition of mitoTEMPO (1.5 mol/kg per day) resulted in a significant time-dependent decrease of blood pressure. MitoTEMPO treatment of hypertensive mice not only reduced blood pressure but also improved endothelial function as evidenced by measurements of endotheliumdependent relaxation evoked by acetylcholine ( Figure 5B ). Of note, mitoTEMPO did not affect endotheliumdependent vasodilatation in normotensive mice ( Figure  5B ) and did not alter the endothelium-independent responses to sodium nitroprusside (Online Figure VII) .
Because the above findings were made in mice treated with Ang II, there was a question as to whether the effect of mitoTEMPO is limited to the Ang II model. We therefore performed additional experiments in mice with DOCA salt hypertension. 35 This model of hypertension differs from Ang II-induced hypertension because it is largely volume dependent and is associated with suppressed plasma renin activity. In these experiments, mitoTEMPO 
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was administered 10 days after the DOCA salt surgery. As in the case of Ang II-induced hypertension, mitoTEMPO reduced blood pressure in DOCA salt mice but did not affect blood pressure in sham-operated mice ( Figure 5C ). ESR studies demonstrated that DOCA salt hypertension decreased endothelial NO production and that mito-TEMPO treatment restored this, while not affecting vascular NO in sham mice ( Figure 5D ).
Overexpression of SOD2 Attenuates Ang II-Induced Endothelial Dysfunction and Hypertension
The above experiments with mitoTEMPO suggest that reducing mitochondrial O 2 . improves endothelial function and hypertension. To confirm this using nonpharmacological means, we investigated production of vascular O 2 . and the development of hypertension in tg SOD2 mice. These animals have a 2-fold increase in SOD2 activity and protein levels. 36 Although basal blood pressures in tg SOD2 and C57Bl/6 mice were similar, the hypertensive response to Ang II was attenuated and delayed in tg SOD2 mice ( Figure 6A ). The production of vascular O 2 . in Ang II-infused tg SOD2 mice was significantly lower compared with C57Blk/6 mice, whereas basal O 2 . level was not different ( Figure 6B ). These data are in keeping with our findings with mitoTEMPO treatment and confirmed the role of mitochondrial O 2 . in vivo.
Discussion
The present study provides the first evidence that scavenging of mitochondrial O 2 . improves endothelial function and reduces hypertension. In this work we found that treatment with either the mitochondria-targeted SOD mimetic mito-TEMPO or overexpression of SOD2 inhibited oxidative stress and prevented the loss of endothelial NO caused by Ang II both in cultured endothelial cells and intact mice. Furthermore, treatment of hypertensive mice with mito-TEMPO after the onset of either Ang II-or DOCA salt-induced hypertension significantly reduced blood pressure and substantially improved endotheliumdependent vasodilatation. Analysis of SOD2 overexpressing transgenic mice confirmed an important role of mitochondrial O 2 . in endothelial function and hypertension.
We have previously shown that Ang II stimulates production of mitochondrial O 2 . . 14 This was dependent on NADPH oxidase activity because siRNA-induced deple- Figure 6C ) in which the NADPH oxidase increases mitochondrial ROS, which further activates the cytoplasmic NADPH oxidase and increases cellular O 2 . production, diminishing NO bioavailability and uncoupling endothelial NO synthase. 37 The effect of mitochondrial ROS on NADPH oxidase activity is quite likely mediated by c-Src 38 which can be stimulated by H 2 O 2 . 33 Indeed, activation of NADPH oxidase has been reported to be a biphasic process in which the first phase requires direct activation by Ang II followed by a second phase of sustained activation that is H 2 O 2 dependent. 39 This could explain why inhibition of mitochondrial H 2 O 2 by mito-TEMPO (Table 2 ) results in decrease of NADPH oxidase activity ( Figure 2C ). Our present findings also indicate that scavenging of mitochondrial O 2 . using mitochondriatargeted antioxidants can interrupt this vicious cycle. Our work is in keeping with prior findings that SOD2 ϩ/Ϫ mice are prone to age-associated and salt-induced hypertension 8 and that treatment with the mitochondria-targeted antioxidant mQ 10 attenuates hypertension in spontaneously hypertensive rats. 40 Our findings also provide additional insight into the role of SOD2 in development of these pathological conditions. We suggest that SOD2 depletion increases mitochondrial O 2 . levels which upregulates NADPH oxidase activity. Indeed, the key role of NADPH oxidase in hypertension and atherosclerosis has been well documented. 34 The synergism between mitochondrial and cellular O 2 . production reported in our work may explain these pathological effects in SOD ϩ/Ϫ mice. Previous studies have shown that the nontargeted SOD mimetic TEMPOL prevents hypertension, renal and vascular dysfunction in several models of hypertension. 24, 41 Importantly, we found that targeting of SOD mimetic to mitochondria provided beneficial effects at a dose 1000-fold lower than previously reported for TEMPOL. This finding is important in two respects. First, it confirms a critical role of the mitochondria in hypertension and endothelial dysfunction. Second, our data demonstrate the feasibility of using 
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very low doses of mitochondrial-targeted antioxidants for therapeutic purposes. Importantly, mitoTEMPO not only attenuated development of hypertension but was also effective in treating hypertension after it was established. This is clinically important because treatment is commonly started in humans after hypertension has developed. Our findings indicate that targeting mitochondrial ROS with agents like mitoTEMPO might therefore be effective in treating human hypertension. This is potentially important because many patients' blood pressure remains poorly controlled despite treatment with multiple drugs. MitoTEMPO and other mitochondria-targeted agents might therefore represent a new class of antihypertensive agent that could add to the currently available therapeutic armamentarium.
MitoTEMPO had no effect on blood pressure in normotensive animals. This is in keeping with the concept that O 2 . does not affect hemodynamics under normal physiological conditions but begins to play a role in pathophysiological states. 42 Indeed, SOD2 overexpression and mitoTEMPO supplementation did not affect basal activity of NADPH oxidase, production of vascular O 2 . or endothelium-dependent relaxation. This is potentially important, because unlike some currently used antihypertensive agents, mitoTEMPO would unlikely cause hypotension in normotensive subjects.
In addition to hypertension, there are many other common conditions including aging, atherosclerosis, diabetes and degenerative neurological disorders in which mitochondrial oxidative stress seems to play a role. 43, 44 Of note, large clinical trials have failed to show a benefit of often-used antioxidants such as vitamin E and vitamin C in many of these conditions, 45, 46 and have paradoxically shown deleterious effects in some trials. 46 There are many potential explanations why these antioxidants have proven ineffective in these studies, but one relates to the fact that agents such as vitamin E and vitamin C are not targeted to sites of ROS generation that are most important in pathological conditions. It is conceivable that the use of SOD mimetics such as mitoTEMPO, targeted to compartments where ROS is generated such as the mitochondria, would be more effective in these conditions. The ability to achieve these effects in relatively low doses might also limit potential untoward effects of antioxidant therapy observed with other agents. 
